SML2604

BAY-885

≥98% (HPLC)

• Synonim(y): BAY 885, BAY885, [2-Amino-4-(trifluoromethoxy)phenyl]{4-[7-(4-methylpiperazin-1-yl)pyrido[3,2-d]pyrimidin-4-yl]piperidin-1-yl}methanone
• Wzór empiryczny (zapis Hilla): C₂₅H₂₈F₃N₇O₂
• Numer CAS: 2307249-33-6
• Masa cząsteczkowa: 515.53
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD32067879
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: O=C(N1CCC(CC1)C2=C3C(C=C(C=N3)N4CCN(CC4)C)=NC=N2)C5=CC=C(C=C5N)OC(F)(F)F
• InChI: 1S/C25H28F3N7O2/c1-33-8-10-34(11-9-33)17-12-21-23(30-14-17)22(32-15-31-21)16-4-6-35(7-5-16)24(36)19-3-2-18(13-20(19)29)37-25(26,27)28/h2-3,12-16H,4-11,29H2,1H3
• InChI key: QXURFIGBRGWPQD-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

ATP site-targeting, potent and selective ERK5 (BMK1, MAPK7) inhibitor.

BAY-885 is an ATP site-targeting, potent and selective ERK5 (BMK1, MAPK7) inhibitor (IC50 = 35 nM with 250 μM ATP; % inhibition at 1 μM = 62/rat Fer, 58/human EphB3, 43/human EphA5, =20/355 kinases) with no BRD4 affinity (20 μM), nor inhibitory potency toward hERG (10 μM) and CYP enzymes (20 μM; CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4). BAY-885 potently inhibits 100 ng/mL EGF-induced, ERK5-dependent MEF2 activity (IC50 = 120 nM; SN12C-MEF2-luc reporter assay).

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable